Table 6.
Distribution of mean ADC, age, and volume in various subgroups of breast cancer patients based on tumor stage, menopausal, and hormonal biomarker status.
| Groups | Number (n) | Age (years) (mean ± SD) | ADC (×10−3 mm2/s) (mean ± SD) | Volume (cm3) (mean ± SD) |
|---|---|---|---|---|
| Premenopausal (Pre) | 119 | 36.4 ± 5.9§ | 1.02 ± 0.18 | 78.50 ± 80.60 |
| Postmenopausal (Post) | 140 | 53.0 ± 7.5§ | 1.02 ± 0.17 | 70.45 ± 87.33 |
| EBC | 52 | 46.7 ± 11.9 | 0.98 ± 0.18@ | 17.67 ± 19.12$ |
| LABC | 207 | 45.0 ± 10.4 | 1.03 ± 0.17@ | 88.17 ± 88.26$ |
| Stage IIA | 52 | 46.7 ± 11.9 | 0.98 ± 0.18 | 17.67 ± 19.12* |
| Stage IIB | 49 | 43.8 ± 10.4 | 0.98 ± 0.12 | 49.34 ± 51.74* |
| Stage IIIA | 45 | 46.0 ± 9.2 | 1.05 ± 0.20 | 82.23 ± 70.04* |
| Stage III (B + C) | 113 | 45.2 ± 10.9 | 1.04 ± 0.17 | 107.21 ± 101.02* |
| HER2+ | 56 | 44.7 ± 10.3 | 1.03 ± 0.16 | 94.60 ± 93.27 |
| HER2− | 84 | 45.1 ± 11.1 | 1.02 ± 0.15 | 84.47 ± 83.74 |
| ER+ | 93 | 47.8 ± 10.8£ | 0.99 ± 0.14 | 54.57 ± 50.62& |
| ER− | 92 | 43.4 ± 10.5£ | 1.02 ± 0.16 | 97.72 ± 104.94& |
| PR+ | 82 | 46.9 ± 11.4 | 1.00 ± 0.14 | 64.81 ± 61.74† |
| PR− | 100 | 44.4 ± 10.2 | 1.02 ± 0.16 | 86.71 ± 100.29† |
| Triple-negative (TN) | 26 | 40.9 ± 9.9+ | 1.07 ± 0.19# | 111.21 ± 116.34¥ |
| Triple-positive (TP) | 13 | 42.8 ± 12.2 | 1.01 ± 0.16 | 61.19 ± 69.51¥ |
| Non-triple-negative (nTN) | 155 | 46.4 ± 10.8+ | 1.00 ± 0.14# | 69.21 ± 74.06¥ |
§,£,+Age P < 0.05: between §pre vs. post; £ER+ vs. ER−; +TN vs. nTN.
@,#ADC P < 0.05: between @EBC vs. LABC; #TN vs. nTN.
$,*,&,†,¥Volume P < 0.05: between $EBC vs. LABC; *stages IIA, IIB, IIIA, and III (B + C); &ER+ vs. ER−; †PR+ vs. PR−; ¥TN vs. nTN and TN vs. TP.
*Significant difference in tumor volume of different tumor stages.